1-14 of 14
Authors: Guangrong Lu
Journal Article
LTBK-05. CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA PATIENTS
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi230, https://doi.org/10.1093/neuonc/noab196.925
Published: 19 November 2021
Journal Article
CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi65, https://doi.org/10.1093/neuonc/noab196.252
Published: 12 November 2021
Journal Article
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii347, https://doi.org/10.1093/neuonc/noaa222.305
Published: 04 December 2020
Journal Article
DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii297, https://doi.org/10.1093/neuonc/noaa222.097
Published: 04 December 2020
Journal Article
CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii45, https://doi.org/10.1093/neuonc/noaa215.182
Published: 09 November 2020
Journal Article
CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii45–ii46, https://doi.org/10.1093/neuonc/noaa215.184
Published: 09 November 2020
Journal Article
NCMP-09. POSTMORTEM STUDY OF ORGAN SPECIFIC TOXICITY IN GLIOBLASTOMA PATIENTS TREATED WITH A COMBINATION OF TEMOZOLOMIDE, BEVACIZUMAB AND IRINOTECAN
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii124–ii125, https://doi.org/10.1093/neuonc/noaa215.521
Published: 09 November 2020
Journal Article
CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Pages ii50–ii51, https://doi.org/10.1093/neuonc/noaa215.204
Published: 09 November 2020
Journal Article
EPID-02. SURVIVAL BENEFIT OF GLIOBLASTOMA PATIENTS AFTER FDA APPROVAL OF BEVACIZUMAB, A POPULATION-BASED STUDY USING SEER, TCR, AND NCDB DATABASES
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi69, https://doi.org/10.1093/neuonc/nox168.280
Published: 06 November 2017
Journal Article
NIMG-24. PATHOLOGY CONFIRMED RADIOGRAPHIC DIAGNOSIS OF TRUE PROGRESSION AND PSEUDO-PROGRESSION MADE BY ADVANCED BRAIN TUMOR IMAGING
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi147, https://doi.org/10.1093/neuonc/nox168.600
Published: 06 November 2017
Journal Article
PATH-31. ELEVATION OF YKL-40, NORMALIZED TO CERULOPLASMIN, IN CEREBROSPINAL FLUID IS ASSOCIATED WITH GLIOBLASTOMA RECURRENCE
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi177, https://doi.org/10.1093/neuonc/nox168.721
Published: 06 November 2017
Journal Article
DRES-08. METFORMIN OVERCOMES TEMOZOLOMIDE RESISTANCE OF GLIOMA CELLS BY MODULATING THE SOX2 PATHWAY
Neuro-Oncology, Volume 18, Issue suppl_6, November 2016, Page vi53, https://doi.org/10.1093/neuonc/now212.218
Published: 07 November 2016
Journal Article
PDCT-16. SURVIVAL BENEFIT WITH TRIPLE CHEMOTHERAPY AND TTFIELDS FOR GLIOBLASTOMA
Neuro-Oncology, Volume 18, Issue suppl_6, November 2016, Page vi149, https://doi.org/10.1093/neuonc/now212.620
Published: 07 November 2016
Journal Article
MPTH-19PHOSPHOLIPASE C BETA 1: A CANDIDATE SIGNATURE GENE FOR PRONEURAL SUBTYPE HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 17, Issue suppl_5, November 2015, Page v142, https://doi.org/10.1093/neuonc/nov222.19
Published: 09 November 2015
